Karen Harman

2.0k total citations
21 papers, 259 citations indexed

About

Karen Harman is a scholar working on Pathology and Forensic Medicine, Genetics and Rheumatology. According to data from OpenAlex, Karen Harman has authored 21 papers receiving a total of 259 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pathology and Forensic Medicine, 5 papers in Genetics and 5 papers in Rheumatology. Recurrent topics in Karen Harman's work include Autoimmune Bullous Skin Diseases (8 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (5 papers) and Urticaria and Related Conditions (4 papers). Karen Harman is often cited by papers focused on Autoimmune Bullous Skin Diseases (8 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (5 papers) and Urticaria and Related Conditions (4 papers). Karen Harman collaborates with scholars based in United Kingdom, United States and Canada. Karen Harman's co-authors include Michael J Sladden, Martin M. Black, Stephen Challacombe, Pepe Shirlaw, Jane Setterfield, Crispian Scully, Tim Goodacre, Anne F. Klassen, Elena Tsangaris and Karen W. Y. Wong Riff and has published in prestigious journals such as The Lancet, British Journal of Dermatology and Developmental Medicine & Child Neurology.

In The Last Decade

Karen Harman

21 papers receiving 250 citations

Peers

Countries citing papers authored by Karen Harman

Since Specialization

Citations

This map shows the geographic impact of Karen Harman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Harman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Harman more than expected).

Fields of papers citing papers by Karen Harman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Harman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Harman. The network helps show where Karen Harman may publish in the future.

Co-authorship network of co-authors of Karen Harman

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Harman. A scholar is included among the top collaborators of Karen Harman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Harman. Karen Harman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association between drugs and vaccines commonly prescribed to older people and bullous pemphigoid: a case–control study 2024 ·British Journal of Dermatology ·(unknown), Yana Vinogradova, Roger Knaggs, Karen Harman, Rowan Harwood, Vibhore Prasad, Monica S M Persson, Grazziela P. Figueredo, (unknown), Sonia Gran	3
2	BT06 Using artificial intelligence to triage skin cancer referrals: outcomes from a pilot study 2023 ·British Journal of Dermatology ·(unknown), (unknown), Karen Harman, (unknown), (unknown)	3
3	The top 10 research priorities for the treatment of bullous pemphigoid, mucous membrane pemphigoid and pemphigus vulgaris in the UK: results of a James Lind Alliance Priority Setting Partnership 2023 ·British Journal of Dermatology ·Karen Harman, (unknown), (unknown), John Dart, (unknown), (unknown), D. J. C. Grindlay, Philip Hampton, (unknown), (unknown), Antonia Lloyd-Lavery, (unknown), Ruth Murphy, Saaeha Rauz, Jane Setterfield, (unknown), (unknown), (unknown)	1
4	Long-term oral prednisolone exposure in primary care for bullous pemphigoid: population-based study 2021 ·British Journal of General Practice ·Monica S M Persson, Karen Harman, Kim S Thomas, Joanne R Chalmers, Yana Vinogradova, Sinéad Langan, Julia Hippisley–Cox, Sonia Gran	3
5	Pachydermodactyly presenting as juvenile idiopathic arthritis in an adolescent man 2021 ·BMJ Case Reports ·(unknown), (unknown), (unknown), (unknown), Karen Harman	2
6	Impact of Completing CLEFT-Q Scales That Ask About Appearance on Children and Young Adults: An International Study 2020 ·The Cleft Palate-Craniofacial Journal ·Anne F. Klassen, Louise Dalton, Tim Goodacre, Karen Harman, Rona Slator, Elena Tsangaris, Douglas J. Courtemanche, Jesse A. Goldstein, Greg Allen, (unknown), Karen W. Y. Wong Riff	10
7	Validation study of bullous pemphigoid and pemphigus vulgaris recording in routinely collected electronic primary healthcare records in England 2020 ·BMJ Open ·Monica S M Persson, Karen Harman, Yana Vinogradova, Sinéad Langan, Julia Hippisley–Cox, Kim S Thomas, Sonia Gran	9
8	Neurocognitive abilities in individuals with Down syndrome-a narrative review 2020 ·The Turkish Journal of Pediatrics ·(unknown), Karen Harman	4
9	Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference 2018 ·Frontiers in Medicine ·Jinmin Lee, Victoria P. Werth, Russell P. Hall, Rüdiger Eming, Janet A. Fairley, David C. Fajgenbaum, Karen Harman, Marcel F. Jonkman, Neil J. Korman, Ralf J. Ludwig, Dédée F. Murrell, Philippe Musette, Haley B. Naik, Christian D. Sadik, Jun Yamagami, (unknown), Aimee Payne	16
10	Establishing Content Validity of the CLEFT-Q: A New Patient-reported Outcome Instrument for Cleft Lip/Palate 2017 ·Plastic & Reconstructive Surgery Global Open ·Elena Tsangaris, Karen W. Y. Wong Riff, Tim Goodacre, Christopher R. Forrest, Marieke M. Dreise, Jonathan M. Sykes, Tristan de Chalain, Karen Harman, A O'Mahony, Andrea L. Pusic, Lehana Thabane, Achilleas Thoma, Anne F. Klassen	49
11	A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial 2017 ·Health Technology Assessment ·Joanne R Chalmers, Fenella Wojnarowska, Gudula Kirtschig, James Mason, Margaret Childs, Diane Whitham, Karen Harman, Anna Chapman, Shernaz Walton, Enno Schmidt, Thomas Godec, Andrew Nunn, Hywel C Williams	13
12	What Is the Chance of a Normal Pregnancy in a Woman Whose Fetus Has Been Exposed to Isotretinoin? 2007 ·Archives of Dermatology ·Michael J Sladden, Karen Harman	35
13	Efficacy of very high dose steroid treatment in a case of Landau-Kleffnersyndrome 2007 ·Developmental Medicine & Child Neurology ·(unknown), (unknown), Karen Harman, Shay Menascu	2
14	Efficacy of very high dose steroid treatment in a case of Landau–Kleffner syndrome 2006 ·Developmental Medicine & Child Neurology ·(unknown), (unknown), Janis Oram Cardy, Tom Humphries, Karen Harman, Shay Menascu	18
15	“Throughcare” for Drug-Using Prisoners in Britain 2004 ·Journal of Offender Rehabilitation ·Karen Harman, Ian Paylor	3
16	A Shift in Strategy 2002 ·Criminal Justice Matters ·Karen Harman, Ian Paylor	4
17	Immunodiagnosis of pemphigus and mucous membrane pemphigoid 2001 ·Acta Odontologica Scandinavica ·Stephen Challacombe, Jane Setterfield, Pepe Shirlaw, Karen Harman, Crispian Scully, Martin M. Black	40
18	Molecular Mapping of the Major Epitopes of BP180 Recognized by Herpes Gestationis Autoantibodies 1999 ·Clinical Immunology ·(unknown), (unknown), (unknown), Mónica Olague-Marchan, (unknown), Karen Harman, Balbir S. Bhogal, Martin M. Black, Luis A. Díaz, George J. Giudice	31
19	Never take things at face value 1998 ·The Lancet ·Karen Harman, (unknown), Martin M. Black	2
20	Scleromyxoedema and thrombotic thrombocytopaenic purpura: two rare conditions both responding to plasma exchange 1998 ·Journal of the European Academy of Dermatology and Venereology ·Karen Harman, I C Abbs, (unknown), Martin M. Black	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact